Δευτέρα 5 Μαρτίου 2018

103PAfatinib is active in osteosarcoma in vitro models

Background: Osteosarcoma is the most common bone tumour and affects younger patients. The combination of chemotherapy with aggressive surgical resection results in survival rates achieving 60%-70% in patients with localized disease. Unfortunately, 30% of osteosarcoma patients present metastatic disease at diagnosis and only 20-30% will become long-term survivors. Therefore, finding new drugs to treat these patients is a research priority. Preclinical and clinical studies suggest involvement of ErbB network aberrations in the aetiology of osteosarcomas. The present study assessed the effect of Afatinib, an irreversible ErbB family blocker, in osteosarcoma cell lines.

http://ift.tt/2FcU2ZZ

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου